Strengths:
- Carboplatin (Kemocarb) 150 mg/15 ml
- Carboplatin (Kemocarb) 450 mg/45 ml
Note: Aluminum reacts with Carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of Carboplatin Injection.
Single-Agent Therapy
Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 IV on day 1 every 4 weeks (alternatively see Formula Dosing). In general, however, single intermittent courses of Carboplatin should not be repeated until 4 weeks after the previous course and/or until the neutrophil count is at least 2000 and the platelet count is at least 100,000.
Combination Therapy with Cyclophosphamide
In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of:
Carboplatin —300 mg/m2 IV on day 1 every 4 weeks for 6 cycles (alternatively see Formula Dosing). Cyclophosphamide (600 mg/m2) IV on day 1 every 4 weeks for 6 cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert.
Intermittent courses of Carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.
